Effects of aggressive cholesterol lowering and low-dose anticoagulation on clinical and angiographic outcomes in patients with diabetes: The Post Coronary Artery Bypass Graft trial

Diabetes

Volumn 48, Issue 6, 2000, Pages 1289-1294

  Hoogwerf, Byron J ^b,d   Waness, Abdelkarim ^d   Cressman, Michael ^d   Canner, Joseph ^b   Campeau, Lucien ^e   Domanski, Michael ^a   Geller, Nancy ^a   Herd, Alan ^g   Hickey, Ann ^f   Hunninghake, Donald B ^c   Knatterud, Genell L ^b   White, Carl ^c  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b MARYLAND MEDICAL RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

^e UNIVERSITÉ DU QUÉBEC À MONTRÉAL   (Canada)

^f CEDARS SINAI MEDICAL CENTER   (United States)

^g BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; CHOLESTEROL; COLESTYRAMINE; HYPOCHOLESTEROLEMIC AGENT; MEVINOLIN; WARFARIN;

ADULT; AGED; ANTICOAGULATION; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; CORONARY RISK; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; POSTOPERATIVE CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK MANAGEMENT; TREATMENT OUTCOME;

ANTICHOLESTEREMIC AGENTS; ANTICOAGULANTS; BIOLOGICAL MARKERS; CORONARY ARTERY BYPASS; CORONARY DISEASE; DIABETIC ANGIOPATHIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; RISK FACTORS; SULFONYLUREA COMPOUNDS;

EID: 0344258474     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.48.6.1289     Document Type: Article

References (45)

1. Garcia MJ, McNamara PM, Gordon T, Kannell WB: Morbidity and mortality in diabetics in the Framingham population. Sixteen year follow-up study. Diabetes 23:105-111, 1974
2. Stamler R, Stamler J: Asymptomatic hyperglycemia and coronary heart disease. J Chron Dis 32:680-691, 1979
3. Panzram G: Mortality and survival in type 2 (non-insulin dependent) diabetes mellitus. Diabetologia 30:123-131, 1987
4. Kannel W: Lipids, diabetes and coronary heart disease: insights from the Framingham Study. Am Heart J 110:1100-1107, 1985
5. Kannel WB, D'Agostino RB, Wilson PWF, Belanger AJ, Gagnon DR: Diabetes, fibrinogen and risk of cardiovascular disease: the Framingham experience. Am Heart J 120:672-676, 1990
6. Stamler J, Vaccaro O, Neaton JD, Wentworth D: Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 16:434-444, 1993
7. Walter DP, Gatling W, Houston AC, Mullee MA, Julious SA, Hill RD: Mortality in diabetic subjects: an eleven-year follow-up of a community-based population. Diabet Med 11:968-973, 1994
8. DeFronzo R, Ferrannini E: Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia and atherosclerotic cardiovascular disease. Diabetes Care 14:173-186, 1991
9. Winegard DL, Barrett-Connor E, Crigui M, Suarez L: Clustering of heart disease risk factors in diabetic compared to non-diabetic adults. Am J Epidemiol 117:19-26, 1983
10. Kaplan NM: The deadly quartet: upper body obesity, glucose intolerance, hypertriglyceridemia and hypertension. Arch Intern Med 149:2114-2120, 1989
11. Davi G, Violi F, Giammarresi C, Putignano E, Nicolosi G, Barbagallo M, Notarbartolo A: Increased plasminogen activator inhibitor antigen levels in diabetic patients with stable angina. Blood Coagul Fibrinolysis 2:41-45, 1991
12. Kwaan HC: Changes in blood coagulation, platelet function, and plasminogen-plasmin system in diabetes (Review). Diabetes 41 (Suppl. 2):32-35, 1992
13. Matsuda T, Morishita E, Jokaji H, Asakura H, Saito M, Yoshida T, Takemoto K: Mechanism on disorders of coagulation and fibrinolysis in diabetes. Diabetes 45 (Suppl. 3):S109-S110, 1996
14. Johnson WE, Pedraza PM, Kayser KL: Coronary artery surgery in diabetics: 281 consecutive patients followed four to seven years. Am Heart J 104: 824-829, 1982
15. Lytle B, Loop FD, Cosgrove DM, Ratliff NB, Easley K, Taylor PC: Long-term (5 to 12 years) serial studies of internal mammary artery and saphenous vein coronary bypass grafts. J Thorac Cardiovasc Surg 89:248-258, 1985
16. Fietsam R, Bassett J, Glover JL: Comparisons of coronary artery surgery in diabetic patients. Am Surg 57:551-557, 1991
17. Morris JJ, Smith LR, Jones RH, Glower DD, Morris PB, Muhlbaier LH, Reves JG, Rankin JS: Influence of diabetes and mammary artery grafting on survival after coronary bypass. Circulation 84 (5 Suppl.):III275-III284, 1991
18. Risum Ø, Abdelnoor M, Svennevig JL, Levorstad K, Gullestad L, Bjømerheim R, Simonsen S, Nitter-Hauge S: Diabetes mellitus and morbidity and mortality risks after coronary artery bypass surgery. Scand J Thor Cardiovasc Surg 30:71-75, 1996
19. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Manninen V, Mäenpaä H, Mälkönen M, Mänttäri M, Norola S, Pasternack A, Pikkarainen J, Romo M, Sjöblom T, Nikkilä EA: Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med 317:1237-1245, 1987
20. Koskinen P, Mänttäri M, Manninen V, Huttunen JK, Heinonen OP, Frick MH: Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care 15:820-825, 1992
21. Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344:1383-1389, 1994
22. Pyörälä K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G, and the Scandinavian Simvastatin Survival Study (4S) Group: Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 20:614-620, 1997
23. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 335:1001-1009, 1996
24. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM Jr: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 279:1615-1622, 1998
25. The Post Coronary Artery Bypass Graft Trial Investigators: The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med 336:153-162, 1997
26. Kaplan EI, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
27. Cox DR: Regression models and life tables (with discussion). J R Stat Soc B 34:187-220, 1972
28. Liang K-Y, Zeger SL: Longitudinal analysis using generalized linear models. Biometrika 73:13-22, 1986
29. Zeger SL, Uang K-Y: Longitudinal data analysis for discrete and continuous outcomes. Biometrics 42:121-130, 1986
30. Winocour PD: Platelet abnormalities in diabetes mellitus. Diabetes 41 (Suppl. 2): 26-32, 1992
31. Brownlee M, Cerami A, Vlassara H: Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 318:1315-1321, 1988
32. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL: Beyond cholesterol: modifications of low-density lipoprotein that increase its atherogenicity (Review). N Engl J Med 320:915-924, 1989
33. Chisolm GM, Irwin KC, Penn MC: Lipoprotein oxidation and lipoprotein-induced cell injury in diabetes. Diabetes 41 (Suppl. 2):61-66, 1992
34. Lyons T: Lipoprotein glycation and its metabolic consequences. Diabetes 41 (Suppl. 2):67-73, 1992
35. ETDRS Study Group: Aspirin effects on mortality and morbidity in patients with diabetes mellitus: Early Treatment Diabetic Retinopathy Study Report 14. JAMA 268:1292-1300, 1992
36. Kuusisto J, Mykkänen L, Pyörälä K, Laakso M: NIDDM and its metabolic control predict coronary heart disease in elderly subjects. Diabetes 43:960-967, 1994
37. Moss SE, Klein R, Klein BE, Meuer SM: The association of glycemia and cause-specific mortality in a diabetic population. Arch Int Med 154:2473-2479, 1994
38. Lento S, Rönnema T, Haffner SM, Pyörälä K, Kallio V, Laakso M: Dyslipidemia and hyperglycemia predict coronary heart disease events in middle-aged patients with NIDDM. Diabetes 46:1354-1359, 1997
39. Knatterud GL, Klimt CR, Goldner MG, Hawkins BS, Weisenfeld S, Kreines K, Haddock L: The University Group Diabetes Program: effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. VIII. Evaluation of insulin therapy: final report. Diabetes 31 (Suppl. 15):1-79, 1982
40. Abraira C, Colwell JA, Nuttall FQ, Sawin CT, Nagel NJ, Comstock JP, Emanuele NV, Levin SR, Henderson W, Lee HS: Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM): results of the feasibility trial. Diabetes Care 18:1113-1123, 1995
41. Abraira C, Colwell J, Nuttall F: Veterans Affairs cooperative study on glycemic control and complications in type II diabetes (VACSDM): results of the feasibility trial. Diabetes Care 18:1113-1123, 1995
42. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichiri M: Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 28:103-117, 1995
43. Turner T, Cull C, Holman R for the United Kingdom Prospective Diabetes Study Group: United Kingdom Prospective Diabetes Study 17: A 9-year update of a randomized controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus. Ann Intern Med 124:136-145, 1996 .
44. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with suphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853, 1998
45. UK Prospective Diabetes Study (UKPDS) Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854-865, 1998